Taiho Pharmaceutical Co has established its subsidiary Taiho Pharma Canada, Inc. inOakville, Ontario. The Canadian operations will be managed by Taiho Oncology, Inc., the U.S. R&D and commercial operations of the Taiho Group, based in Princeton, N.J.

The establishment of Taiho Pharma Canada was motivated by the recent successful NDA approval and commercial launch of Lonsurf (R) (IND code: TAS-102, nonproprietary names: trifluridine and tipiracil hydrochloride), Taiho's first cancer product in the U.S. Taiho Pharma Canada will prepare for an NDA submission and for potential commercialization of the product in Canada.

"We are delighted to establish our permanent presence in Canada," said Ross Glover, VP and General Manager of Taiho Pharma Canada. "We believe Taiho Pharma Canada has a great deal to contribute to the health and well-being of Canadians and we look forward to building a strong presence in Canada."